http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
An Soomin,Kim Youn-Jung,Han Ga Young,Eo Wankyu 한국기초간호학회 2022 Journal of korean biological nursing science Vol.24 No.1
Purpose: To determine the prognostic role of muscle area and muscle radiation attenuation in the erector spinae (ES) and multifidus (MF) muscles in patients undergoing gastrectomy. Methods: Patients with stage I-III gastric cancer undergoing gastrectomy were retrospectively enrolled in this study. Clinicopathologic characteristics were collected and analyzed. Both paraspinal muscle index of ES/MF muscles (PMIEM) and paraspinal muscle radiation attenuation in the same muscles (PMRAEM) were analyzed at the 3rd lumbar level using axial computed tomographic images. Cox regression analysis was applied to estimate overall survival (OS) and disease-free survival (DFS). Results: There was only a weak correlation between PMIEM and PMRAEM (r=0.28). Multivariate Cox regression revealed that PMRAEM, but not PMIEM, was an important determinant of survival. PMRAEM along with age, tumor-node-metastasis (TNM) stage, perineural invasion, and serum albumin level were significant determinants of both OS and DFS that constituted Model 1. Harrell’s concordance index and integrated area under receiver operating characteristic curve were greater for Model 1 than for Model 2 (consisting of the same covariates as Model 1 except PMRAEM) or Model 3 (consisting of only TNM stage). Conclusion: PMRAEM, but not PMIEM, was an important determinant of survival. Because there was only a weak correlation between PMIEM and PMRAEM in this study, it was presumed that they were mutually exclusive. Model 1 consisting of age, TNM stage, perineural invasion, serum albumin level, and PMRAEM was greater than nested models (i.e., Model 2 or Model 3) in predicting survival outcomes.
TERT promoter mutations and long-term survival in patients with thyroid cancer
Kim, Tae Hyuk,Kim, Young-Eun,Ahn, Soomin,Kim, Ji-Youn,Ki, Chang-Seok,Oh, Young Lyun,Kim, Kyunga,Yun, Jae Won,Park, Woong-Yang,Choe, Jun-Ho,Kim, Jung-Han,Kim, Jee Soo,Kim, Sun Wook,Chung, Jae Hoon Bioscientifica 2016 Endocrine-related cancer Vol.23 No.10
<P><I>TERT</I> promoter mutations are emerging prognostic biomarkers in multiple cancers and are found in highly aggressive thyroid cancer. Our aim is to investigate the prognostic value of these mutations for the outcome of thyroid cancer-related mortality in a large cohort of thyroid cancer patients. This was a retrospective study of 409 patients (393 with differentiated thyroid cancer) with a median age of 44 years (range 16-81 years) and median follow-up of 13 years (interquartile range 11-16 years). Analyses of associations between mutational status and various clinicopathological variables were performed. <I>TERT</I> promoter mutations were identified in 32 (9.8%) papillary, 11 (16.7%) follicular and seven (43.8%) poorly differentiated/anaplastic thyroid cancer patients. The presence of <I>TERT</I> promoter mutations was associated with factors such as increased age (<I>P</I> < 0.001), extrathyroidal invasion (<I>P</I> = 0.01), increased stage at diagnosis (<I>P</I> < 0.001) and dedifferentiated histological type (<I>P</I> = 0.001). A <I>TERT</I> promoter mutation was independently associated with poorer overall survival in patients with differentiated thyroid cancer (10-year survival rate, 66.2% vs 98.3% for wild type; adjusted HR, 7.18; 95% CI: 2.77-18.59) and in patients with papillary cancer (74.2% vs 99.3%; 14.20; 3.03-66.68). Concomitant <I>TERT</I> and <I>BRAF</I> mutations worsened the survival rate of patients with papillary cancer (82.6% vs 99.4% for exclusively <I>BRAF</I> mutation alone; 5.62; 1.85-17.09). In conclusion, the presence of <I>TERT</I> promoter mutations is independently associated with increased mortality in patients with differentiated thyroid cancer. The results suggest that inclusion of <I>TERT</I> promoter mutation analysis with conventional clinicopathological evaluation can lead to better prognostication and management for individual patients.</P>
Ahn, Soomin,Kim, Hyun Jeong,Kim, Milim,Chung, Yul Ri,Kang, Eunyoung,Kim, Eun-Kyu,Kim, Se Hyun,Kim, Yu Jung,Kim, Jee Hyun,Kim, In Ah,Park, So Yeon Korean Cancer Association 2018 Cancer Research and Treatment Vol.50 No.4
<P><B>Purpose</B></P><P>Alteration of biomarker status after primary systemic therapy (PST) is occasionally found in breast cancer. This study was conducted to clarify the clinical implications of change of biomarker status in breast cancer patients treated with PST.</P><P><B>Materials and Methods</B></P><P>The pre-chemotherapeutic biopsy and post-chemotherapeutic resection specimens of 442 breast cancer patients who had residual disease after PST were included in this study. The association between changes of biomarker status after PST and clinicopathologic features of tumors, and survival of the patients, were analyzed.</P><P><B>Results</B></P><P>Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status changed after PST in 18 (4.1%), 80 (18.1%), and 15 (3.4%) patients,respectively. ER and PR mainly underwent positive to negative conversion,whereas HER2 status underwent negative to positive conversion. Negative conversion of ER and PR status after PST was associated with reduced disease-free survival. Moreover, a decline in the Allred score for PR in post-PST specimens was significantly associated with poor clinical outcome of the patients. HER2 change did not have prognostic significance. In multivariate analyses, negative PR status after PST was found to be an independent adverse prognostic factor in the whole patient group, in the adjuvant endocrine therapy-treated subgroup, and also in pre-PST PR positive subgroup.</P><P><B>Conclusion</B></P><P>ER and HER2 status changed little after PST, whereas PR status changed significantly. In particular, negative conversion of PR status was revealed as a poor prognostic indicator, suggesting that re-evaluation of basic biomarkers is mandatory in breast cancer after PST for proper management and prognostication of patients.</P>
Kim, Suhee,Kim, Hyunwoo,Lee, Soo-Hyeon,Cho, Ilhan,Kang, Seongwoo,Bae, Junwoo,Kim, Woosun,Ahn, Soomin,Choi, Jihye,Kim, Sang-Ki,Do, Yoonjung,Yoo, Jae Gyu,Park, Jinho,Yu, DoHyeon 한국조명·전기설비학회 2017 한국조명·전기설비학회 학술대회논문집 Vol. No.
<P>Acute lymphocytic leukemia (ALL) is uncommon lymphoid malignancy in dogs, and its diagnosis is challenging. A 14-year-old spayed female mixed breed dog was transferred to a veterinary medical teaching hospital for an immediate blood transfusion. The dog showed lethargy, pale mucous membranes, and a weak femoral pulse. Complete blood count revealed non-regenerative anemia and severe leukopenia with thrombocytopenia. ALL was tentatively diagnosed based on the predominance of immature lymphoblasts on blood film examination. For confirmation of lymphoid malignancy, PCR for antigen receptor rearrangement (PARR) on a peripheral blood sample and flow cytometry analysis were performed after blood transfusion. Flow cytometry analysis revealed that lymphocyte subsets were of normal composition, but PARR detected a T-cell malignancy. The dog was diagnosed with ALL and survived 1 wk after diagnosis. In conclusion, after blood transfusion, flow cytometry was not a reliable diagnostic method for an ALL dog, whereas PARR could detect lymphoid malignancy. Our results suggest that PARR should be the first-line diagnostic tool to detect canine lymphoid malignancy after a blood transfusion.</P>
Kim, Kihwan,Kim, Juran,Gang, Myeng Gil,Kim, Se-Ho,Song, Soomin,Cho, Yunae,Shin, Donghyeop,Eo, Young-Joo,Jeong, Inyoung,Ahn, Seung Kyu,Cho, Ara,Kim, Jayeong,Yoon, Seokhyun,Choi, Pyuck-Pa,Jo, William,Ki Elsevier 2019 Solar energy materials and solar cells Vol.195 No.-
<P><B>Abstract</B></P> <P>In this work, copper indium gallium selenide (Cu(In,Ga)Se<SUB>2</SUB>; CIGS) absorbers were grown on polyimide (PI)/molybdenum substrates by a three-stage co-evaporation process at various temperatures, film formation was systemically studied using various advanced characterization methods such as transmission electron microscopy, micro-Raman spectroscopy, Kelvin probe force microscopy, and atom probe tomography. The CIGS films on PI were found to exhibit considerable physical and electrical variations with respect to the process temperature of three-stage co-evaporation. In particular, when the process temperature reached 400 °C, the CIGS absorber on PI began to exhibit controlled microstructure and intergrain properties. By adjusting the microstructure and intergrain properties of the absorber films by means of the process temperature of three-stage co-evaporation, flexible CIGS solar cells on PI with an efficiency of 16.7% (with anti-refection coating) were achieved.</P> <P><B>Highlights</B></P> <P> <UL> <LI> CIGS absorber films were grown on flexible polyimide/molybdenum substrates. </LI> <LI> Low-temperature three-stage process (≤440 °C) with extrinsic Na addition was used to CIGS growth. </LI> <LI> CIGS film evolution was systemically observed using advanced material characterization techniques. </LI> <LI> Highly efficient CIGS cells on flexible polyimide substrates were realized while maintaining process manufacturability. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Kim, Sae-Um,Kim, Kyoung-Rok,Kim, Ji-Won,Kim, Soomin,Kwon, Yong-Uk,Oh, Deok-Kun,Park, Jin-Byung American Chemical Society 2015 Journal of agricultural and food chemistry Vol.63 No.10
<P>Secondary metabolites of plants are often difficult to synthesize in high yields because of the large complexity of the biosynthetic pathways and challenges encountered in the functional expression of the required biosynthetic enzymes in microbial cells. In this study, the biosynthesis of plant oxylipins-a family of oxygenated unsaturated carboxylic acids-was explored to enable a high-yield production through a designed microbial synthetic system harboring a set of microbial enzymes (i.e., fatty acid double-bond hydratases, alcohol dehydrogenases, Baeyer-Villiger monooxygenases, and esterases) to produce a variety of unsaturated carboxylic acids from ?-linolenic acid. The whole cell system of the recombinant Escherichia coli efficiently produced (6Z,9Z)-12-hydroxydodeca-6,9-dienoic acid (<B>7</B>), (Z)-9-hydroxynon-6-enoic acid (<B>15</B>), (Z)-dec-4-enedioic acid (<B>17</B>), and (6Z,9Z)-13-hydroxyoctadeca-6,9-dienoic acid (<B>2</B>). This study demonstrated that various secondary metabolites of plants can be produced by implementing artificial biosynthetic pathways into whole-cell biocatalysis.</P>
Kim, Seung Tae,Kim, Kyoung‐,Mee,Kim, Nayoung K.D.,Park, Joon Oh,Ahn, Soomin,Yun, Jae‐,Won,Kim, Kyu‐,Tae,Park, Se Hoon,Park, Peter J.,Kim, Hee Cheol,Sohn, Tae Sung,Choi, Dong Il,Cho, AlphaMed Press 2017 The oncologist Vol.22 No.10
<P>Molecular profiling of actionable mutations in refractory cancer patients has the potential to enable 'precision medicine,' wherein individualized therapies are guided based on genomic profiling. The molecular-screening program was intended to route participants to different candidate drugs in trials based on clinical-sequencing reports. In this screening program, we used a custom target-enrichment panel consisting of cancer-related genes to interrogate single-nucleotide variants, insertions and deletions, copy number variants, and a subset of gene fusions. From August 2014 through April 2015, 654 patients consented to participate in the program at Samsung Medical Center. Of these patients, 588 passed the quality control process for the 381-gene cancer-panel test, and 418 patients were included in the final analysis as being eligible for any anticancer treatment (127 gastric cancer, 122 colorectal cancer, 62 pancreatic/biliary tract cancer, 67 sarcoma/other cancer, and 40 genitourinary cancer patients). Of the 418 patients, 55 (12%) harbored a biomarker that guided them to a biomarker-selected clinical trial, and 184 (44%) patients harbored at least one genomic alteration that was potentially targetable. This study demonstrated that the panel-based sequencing program resulted in an increased rate of trial enrollment of metastatic cancer patients into biomarker-selected clinical trials. Given the expanding list of biomarker-selected trials, the guidance percentage to matched trials is anticipated to increase.</P>